Invictus MD Announces Completion of its Commitment to Acquire 33.33% of Licensed Producer AB Laboratories Inc.

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update

Invictus MD’s Acreage Pharms Ltd. Receives Development Permit for Phase 2 and Provides Update

 

FOREX INVESSTORS  PRESS RELEASE  Acreage Pharms Ltd   INVICTUS MD STRATEGIES CORP. (“Invictus MD” or the “Company”) (TSXV: IMH; OTC: IVITF; FRA: 8IS) is pleased to announce that its licensed production facility under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), Acreage Pharms Ltd. (“Acreage Pharms”) located near Edson, Alberta, utilizing a multi-room indoor perpetual growing methodology, will begin its first harvest the first week of August, with the second harvest occurring the following week.  The company anticipates a harvest to take place approximately monthly going forward.

Invictus MD is further pleased to announce that Acreage Pharms has received its development permit for Phase 2 and has broken ground initiating construction on its 27,800 square foot purpose built, multiple room production facility. All contractors and suppliers necessary for the project have been scheduled. Invictus MD has committed to investing $6.0 million, which will be used to fund the costs of constructing the production facility.

“Following our successful harvest at the AB Laboratories production facility as announced earlier, and by securing the development permit for our Alberta production facility, with $30 million cash available and the majority earmarked for building production capacity, Invictus MD is prepared for an exciting year of growth,” said Dan Kriznic, Executive Chairman and CEO, Invictus MD. “Led by one of the industry’s most experienced teams, we are strongly focused on building our shareholder value. With 250 acres of cultivation space that stretches from Alberta to Ontario, allowing for purpose built production facilities rather than retrofitting existing buildings, our large land package allows for building cultivation facilities as demand increases and we will continue the disciplined but agile execution of our business strategy, and further establishing our leadership position as Canada’s cannabis company” added Kriznic.



Acreage Pharms Ltd

Invictus MD also announced that Mr Paul Sparkes and Mr. Josef W. Hocher have been appointed to the Company’s Board of Directors.

Mr. Paul Sparkes is an accomplished business leader with over twenty five years’ experience in media, public affairs, venture capital, and Canada’s political arena. He is Currently President of Otterbury Holdings Inc., a corporation advising growth companies in the private and public markets.  Most recently Mr. Sparkes was Executive Vice Chair, Director and co-founder of Difference Capital Financial, a TSX-listed specialty finance company. Previously, Mr. Sparkes was Executive Vice President, Corporate Affairs for CTVglobemedia (now Bellmedia). Prior to joining Bell Globemedia in 2001 as Group Vice-President, Public Affairs, Mr. Sparkes held senior positions in public service, including with the Government of Canada and the Government of Newfoundland and Labrador. From 1996 to 2001, he served in the Office of the Prime Minister of Canada as Director of Operations, and Special Assistant for Atlantic Canada. Mr. Sparkes also served as Executive Assistant to two Premiers of Newfoundland and Labrador. Mr. Sparkes sits on several public and private boards including Thunderbird Entertainment (private), Bluedrop Performance Learning Inc. (TSXV: BPL), Antler Gold Inc (TSXV:ANTL.V) BlastGard International Inc (BLGA-US) and is a former board member of the Liquor Control Board of Ontario ( LCBO).

Mr. Josef W. Hocher was a founder of Buried Hill Energy, an international oil and gas company, where he acted as co-chief executive in creating, developing and implementing the organization’s strategic direction.  He continues to serve as the Senior Independent Director and is also either a Chair or a member of various committees. Mr. Hocher also founded Hitic Energy Ltd., and was a partner at Osler, Hoskin & Harcourt LLP. He currently serves as Chairman of Orthoshop Geomatics Ltd., a geomatics services company; holds the position of Chief Commercial Officer at Field Upgrading Limited and Western Hydrogen Limited and since 2016, has been a Partner at Cassels, Brock & Blackwell LLP.

About Invictus MD Strategies Corp.

Invictus MD Strategies Corp. is focused on two main verticals within the burgeoning Canadian cannabis sector: Licensed Producers under the ACMPR, including its wholly owned subsidiary Acreage Pharms Ltd., as well as its investment in the fully licensed facility AB Laboratories Inc.; and Fertilizer and Nutrients through Future Harvest Development Ltd.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
Dan Kriznic
Executive Chairman & CEO

Larry Heinzlmeir
Vice President, Marketing & Communications
604-537-8676

Cautionary Note Regarding Forward-Looking Statements: Statements contained in this news release that are not historical facts are “forward-looking information” or “forward-looking statements” (collectively, “Forward-Looking Information”) within the meaning of applicable Canadian securities legislation and the United States Private Securities Litigation Reform Act of 1995. Forward Looking Information includes, but is not limited to, disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action; and the plans for completion of the Offering, expected use of proceeds and business objectives. In certain cases, Forward-Looking Information can be identified by the use of words and phrases such as “anticipates”, “expects”, “understanding”, “has agreed to” or variations of such words and phrases or statements that certain actions, events or results “would”, “occur” or “be achieved”. Although Invictus has attempted to identify important factors that could affect Invictus and may cause actual actions, events or results to differ materially from those described in Forward-Looking Information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended, including, without limitation, the risks and uncertainties related to the Offering not being completed in the event that the conditions precedent thereto are not satisfied. In making the forward-looking statements in this news release, Invictus has applied several material assumptions, including the assumptions that (1) the conditions precedent to completion of the Offering will be fulfilled so as to permit the Offering to be completed on or about June 1, 2017; (2) all necessary approvals will be obtained in a timely manner and on acceptable terms; and (3) general business and economic conditions will not change in a materially adverse manner. There can be no assurance that Forward-Looking Information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on Forward-Looking Information. Except as required by law, Invictus does not assume any obligation to release publicly any revisions to Forward-Looking Information contained in this news release to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



 Digipath Receives Recreational Testing License  (DIGP), an independent testing laboratory and media firm focused on the burgeoning

Digipath, Inc. (DIGP) Receives Recreational Testing License and Renews Medical License

Digipath Receives Recreational Testing License and Renews Medical License as Retail Cannabis Market Launches in Nevada

 Digipath Receives Recreational Testing License  <span data-recalc-dims=(DIGP), an independent testing laboratory and media firm focused on the burgeoning" width="300" height="172" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/07/94753.jpg?resize=300%2C172 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/07/94753.jpg?w=500 500w" sizes="(max-width: 300px) 100vw, 300px" />

FOREX  INVESTORS PRESS RELEASE    Digipath Receives Recreational Testing License  (DIGP), an independent testing laboratory and media firm focused on the burgeoning cannabis market, is pleased to announce that it has both received its recreational testing license and renewed its existing medical testing license alongside the launch of the highly anticipated retail cannabis market in Nevada which began on July 1, 2017.

DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath, Inc. digital pathology portfolio includes PathScope(TM), PathCloud(TM), PathReview(TM), and PathConsult(TM) digital platforms to share and store archive tissue images. DigiPath, Inc. is expanding into new lines of business associated with the research, development, licensing and operation of botanical and nutrapharmaceutical products and services. (PRNewsFoto/Digipath, Inc.)

Nevada’s medical cannabis market currently serves just over 28,000 patients that use the plant and its derivative products for the treatment of a variety of maladies. However, with the launch of the retail marijuana market, anyone over the age of 21 with valid identification can purchase cannabis products. This opens the market to a much larger portion of Nevada’s 2 million residents over the age of 21, as well as a significant segment of the more than 42 million tourists and convention goers that visit the state annually.



Digipath Receives Recreational Testing License

The Nevada Dispensary Association estimated that statewide adult-use sales were between $3 to $5 million in the first weekend. As sales continue to rise, suppliers of cannabis products will be moving rapidly to meet the increased demand, necessitating a much larger demand for the laboratory testing of these products. Similar market shifts occurred with the launch of adult-use cannabis markets in Colorado, Oregon, and Washington State, and Nevada is expected to be one of the largest adult-use markets in the United States by the end of 2018.

Todd Denkin, President of Digipath, commented, “It’s really exciting to be a part of history as Nevadans get what they voted for in 2016. The entire medical marijuana community has been working overtime to satisfy this new retail customer base. With the highest capacity and the fastest turnaround time of any lab in Nevada, Digipath Labs is ready for the onslaught of both retail and medical cannabis and cannabis based products.”

About Digipath, Inc.
Digipath, Inc. is an independent cannabis testing and media firm that supports the cannabis industry’s best practices for reliable testing and delivers cannabis news coverage and education about the cannabis industry. Digipath’s two business units are Digipath Labs and TNM News Corp. Digipath Labs™ is working to set the industry standard for testing all forms of cannabis-based products using FDA-compliant laboratory equipment and proprietary standard operating procedures (SOP) to ensure product safety and efficacy. TNM News Corp. has pioneered a cannabis-focused news network, The National Marijuana News, which delivers news, interviews, and education on all things cannabis.Like up on FACEBOOK


logo



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Deveron Receives National Approval Deveron UAS Corp. (CSE:DVR) (CSE:DVR.CN) (CNSX:DVR) ("Deveron" or the "Company"), is pleased to announce that it has been granted approval as a Compliant Operator under its Special Flight

Deveron Receives National Approval to Operate Drones Across Canada

|Chart | Calendar   | TRADE NOW | FORCAST | STOCKS

Deveron Receives National Approval to Operate Drones Across Canada

 

Deveron Receives National Approval  Deveron UAS Corp. <span data-recalc-dims=(CSE:DVR) (CSE:DVR.CN) (CNSX:DVR) ("Deveron" or the "Company"), is pleased to announce that it has been granted approval as a Compliant Operator under its Special Flight " width="300" height="300" srcset="https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/05/6lCYzUQr_400x400-Small.jpg?resize=300%2C300 300w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/05/6lCYzUQr_400x400-Small.jpg?resize=150%2C150 150w, https://i1.wp.com/investorsbuz.com/wp-content/uploads/2017/05/6lCYzUQr_400x400-Small.jpg?w=480 480w" sizes="(max-width: 300px) 100vw, 300px" />

BUZ INVESTORS PRESS RELEASE   Deveron Receives National Approval  Deveron UAS Corp. (CSE:DVR) (CSE:DVR.CN) (CNSX:DVR) (“Deveron” or the “Company”), is pleased to announce that it has been granted approval as a Compliant Operator under its Special Flight Operations Certificate (“SFOC”) for the operation of a small unmanned airborne vehicle (“UAV” or “Drone”) system within visual line-of-sight, issued under the authority of the Minister, Transport Canada, pursuant to the Aeronautics Act. The certificate is valid for aerial data collection and surveying throughout Canada, and meets the highest level of approvals under Transport Canada’s regulatory environment related to UAV activities.

Deveron is one of the first companies in the country to receive this Compliant status as well as one of the first to receive Compliant approval using the senseFly eBee UAV system.



Deveron Receives National Approval

“Our focus is to grow a standardized network of drones to enable scalable data collection at the enterprise level in agriculture,” commented Deveron’s Co-founder and Head of UAS Agriculture, Norm Lamothe. “Being one of the first nationally compliant operators in Canada is a huge achievement for us and we look forward to continuing to provide commercial feedback in safely operating a national drone data service company. Additionally, we couldn’t be more thrilled to achieve compliance with the senseFly platform and are excited about continuing to bring their global leadership in the drone space directly to our customers”.

“This award of national compliance is excellent news for Deveron UAS. The company has rapidly become a major and respected player on the North American agricultural scene and its SFOC will give it the flexibility required to continue servicing clients at scale,” said Jean-Christophe Zufferey, the CEO of senseFly. “From our side, we are delighted to play a small part in the company’s ongoing success through producing fleet-friendly, end-to-end eBee drone platforms that Deveron’s team can rely on for accurate, consistent data collection across Canada and beyond.”

About Deveron UAS:

Deveron is a Transport Canada Compliant Operator enterprise drone data services company focused on agriculture, offering the opportunity to increase yields and reduce costs using sophisticated Unmanned Aerial Systems (“UAS” or “drones”), sensors, software and analytics. Deveron’s drone data service network allows enterprise level customers to obtain on-demand, actionable data without exposure to technology and capital risks. The Company is focused on building a standardized constellation of drones and sensors to provide data in North America.

For more information and to join our community, please visit www.deveronuas.com

Like up on FACEBOOK


logo

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




BUZ INVESTORS PRESS RELEASE Scorpion Grow Lights Future Farm Technologies Inc. (the “Company” or “Future Farm”) ( OTCQB : FFRMF ) is pleased to announce that it is sold out of its exclusive line of Scorpion LED COB Grow Lights

$FFRMF Sold Out of Its Scorpion Grow Lights and Receives ETL Certification

Future Farm Sold Out of Its Scorpion Grow Lights and Receives ETL Certification

BUZ INVESTORS PRESS RELEASE Scorpion Grow Lights Future Farm Technologies Inc. (the “Company” or “Future Farm”) ( OTCQB : FFRMF ) is pleased to announce that it is sold out of its exclusive line of Scorpion LED COB Grow Lights

BUZ INVESTORS PRESS RELEASE Scorpion Grow Lights Future Farm Technologies Inc. (the “Company” or “Future Farm”) ( OTCQB : FFRMF ) is pleased to announce that it is sold out of its exclusive line of Scorpion LED COB Grow Lights, which recently passed Intertek’s ETL certification process. Intertek is one of the world’s largest testing, inspection and certification companies and its ETL Mark is proof of product compliance to North American safety standards. With the ETL testing complete, Future Farm is now able to implement its planned sales and marketing strategy into the fast growing North American cannabis cultivation market.
With its ETL certification, Future Farm’s Scorpion line of LED indoor grow lights is approved for retail sale across all of North America, which opens up its biggest market for rapid growth. Future Farm’s ETL approved LED COB Grow Lights cover a broad spectrum of wattages (including 120W, 245W, 315W, 375W, 495W, 560W) for growing clones or flowering plants. The Company is well positioned to satisfy any cultivator’s needs, from the small grower to the large industrial scale grower.

With twenty-six U.S. states and the District of Columbia broadly legalizing marijuana use, the increased demand on energy consumption in pro-cannabis territories is expected to skyrocket, continuing the trend towards LED “grow light” solutions that reduce energy costs while increasing yields. Analysts forecast the global LED lighting market for horticulture application to grow at a CAGR of 22.55% during the period 2016-2020.



Scorpion Grow Lights

“The cultivation of cannabis is an energy-intensive industry,” said William Gildea, CEO of Future Farm. “A recent study revealed that legalized indoor marijuana-growing operations account for 1% of total electricity use in the United States, at a cost of $6 billion1annually. As the cannabis industry continues its rapid global expansion, cultivation facilities are increasingly turning to LEDs to reduce energy costs and boost profits, and we intend to be a part of this growing market.”

“Our Scorpion Grow Lights have been in high-demand, and having ETL certification means Future Farm can carry the needed inventory to meet the demand,” says Rob Huston of Future Farm’s LED Canada Division. “A lot of time and research has gone into this product and I am very happy that we have passed Intertek’s high certification standards. We have had amazing feedback from many experienced cultivators considering the switch to LED, and are impressed by the results of our Scorpion COB fixtures. Now that the certification is complete, we can move forward with our distribution plans.”

About Chip On Board (COB):
LEDs compete with traditional lighting sources in a number of ways, including greater energy efficiency, longer lifetime, and smaller size. However, the one drawback that has vexed many lighting designers is cost, which is a key reason why LED manufacturers continue to innovate to improve economies of scale. One of the newest packaging solutions designed to help lower costs is Chip on Board (“COB”) light source modules, in which the LED chips are in the form of a semiconductor chip that is neither encased nor connected but directly mounted onto a PCB or, more generally, a substrate. This packaging style also provides several related benefits, such as greater design flexibility, better light distribution, and simpler manufacturing processes.

1Lawrence Berkley National Laboratory

About Future Farm
The Company’s business model includes developing and acquiring technologies that will position it as a leader in the evolution of Controlled Environment Agriculture (CEA) for the global production of various types of plants. Future Farm provides scalable, indoor CEA systems that utilize minimal land, water and energy regardless of climate, location or time of year and are customized to grow an abundance of crops close to consumers, therefore minimizing food miles and its impact to the environment. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generate yields up to 10 times greater per square foot of land. The contained system provides many other benefits including seed to sale security, scalability, consistency due to year-round production, cost control, product safety and purity by eliminating environmental variability.Like up on FACEBOOK


Ebates Coupons and Cash Back

Market quotes are powered by
TradingView.com



Tech Stocks ( GOOG)   (MSFT ) ( AAPL ) (BBRY ) ( gopro )  ( WDC )




Buz Investors CMED, receives export permits CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) today announced the receipt, through its wholly-owned subsidiary Prairie Plant Systems Inc., of

Medical cannabis company, CMED, receives export permits and purchase orders for distribution to Australia and the Cayman Islands

Medical cannabis company, CMED, receives export permits and purchase orders for distribution to Australia and the Cayman Islands

 

Buz Investors CMED, receives export permits CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) today announced the receipt, through its wholly-owned subsidiary Prairie Plant Systems Inc., of

Buz Investors  CMED, receives export permits CanniMed Therapeutics Inc. (“CanniMed” or the “Company”) (TSX: CMED) today announced the receipt, through its wholly-owned subsidiary Prairie Plant Systems Inc., of the Company’s first two Health Canada issued export permits for medical cannabis oils. In addition, the Company has received initial purchase orders for all three CanniMed® Oils for distribution to both Australia and the Cayman Islands for pharmacy dispensing.

“We continue to execute our business plan with today’s milestone announcement, positioning CanniMed as a leading global provider of cannabinoid-based medicines,” said Brent Zettl, President and CEO of the Company. “Our focus on GMP-compliant manufacturing, which includes extensive quality controls, is a standard that international partners are demanding. These initial orders, while small in scale, represent a significant step for the Company and pave the way for what we believe will be a significant distribution channel for our CanniMed oil products.”



OTHER STORIES BUZ INVESTORS FOLLOW

CMED, receives export permits 

These two Health Canada-issued export permits will include all three of the CanniMed® Oil products (CanniMed® Oil 18:0, CanniMed® Oil 10:10 and CanniMed® Oil 1:20). By June 30, 2017, the Company will have shipped 3,600 ml and 12,960 ml of CanniMed® Oils to Australia and the Cayman Islands respectively.

The Company expects to be able to provide additional details with respect to these developing opportunities within the coming weeks.

About CanniMed Therapeutics Inc.

The Company is a Canadian-based, international plant biopharmaceutical company and a leader in the Canadian medical cannabis industry, with 15 years of pharmaceutical cannabis cultivation experience, state-of-the-art, GMP-compliant plant production processes and world class research and development platforms with a wide range of pharmaceutical-grade cannabis products. In addition, the Company has an active plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications.

CanniMed Ltd., through its subsidiaries, was the first producer to be licensed under the Marihuana for Medical Purposes Regulations, the predecessor to the current Access to Cannabis for Medical Purposes Regulations. It was the sole supplier to Health Canada under the former medical marijuana system for 13 years, and has been producing safe and consistent medical marijuana for thousands of Canadian patients, with no incident of product diversion or recalls.

For more information, please visit our websites: www.cannimed.ca (patients) and www.cannimedtherapeutics.com (investors).

Notice Regarding Forward Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws.  All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.  Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved.

Forward-looking statements are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of CanniMed Therapeutics Inc. to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks described in CanniMed Therapeutics Inc.’s documents filed with applicable Canadian securities regulatory authorities which may be viewed at www.sedar.com . The forward-looking statements included in this news release are made as of the date of this news release.  CanniMed Therapeutics Inc. does not undertake to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise, unless required by applicable securities legislation.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )




Innocoll AG (INNL) Receives Refusal to File Letter from FDA

Innocoll AG (INNL) Receives Refusal to File Letter from FDA

Innocoll AG (INNL) Receives Refusal to File Letter from FDA

  • Buz Investors Innocoll AG (NASDAQ: INNL) received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.
  • Upon preliminary review, the FDA determined that the application, which was submitted in October 2016, was not sufficiently complete to permit a substantive review.
  • In the Refusal to File letter, the FDA indicated among other things, that XARACOLL should be characterized as a drug/device combination, which would require that the Company submit additional information.

Innocoll AG

Buz Investors Innocoll AG (NASDAQ: INNL) received a Refusal to File letter from the United States Food and Drug Administration <span data-recalc-dims=(FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain." width="300" height="172" srcset="https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/01/AAEAAQAAAAAAAAMDAAAAJGUzMTEzMTYyLTA3MTEtNDM3OS04Mzc0LTdlMzRhNWU4ZDUzYw.jpg?resize=300%2C172 300w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/01/AAEAAQAAAAAAAAMDAAAAJGUzMTEzMTYyLTA3MTEtNDM3OS04Mzc0LTdlMzRhNWU4ZDUzYw.jpg?w=698 698w" sizes="(max-width: 300px) 100vw, 300px" />

Innocoll AG (NASDAQ:INNL), a global, commercial-stage, specialty pharmaceutical company, today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.

Other Stories Buz Traders Share

Innocoll AG

Upon preliminary review, the FDA determined that the application, which was submitted in October 2016, was not sufficiently complete to permit a substantive review.  In the Refusal to File letter, the FDA indicated among other things, that XARACOLL should be characterized as a drug/device combination, which would require that the Company submit additional information.  The company will request a Type A meeting with the FDA to respond to several issues believed to be addressable and seek clarification of what additional information, if any, will be required.  Additional details will be disclosed in the future after discussions with the FDA.

“We expect to work with the FDA over the coming weeks in an effort to address the open issues and to define a path forward for a successful re-filing of our application at the earliest point in time,” said Tony Zook, CEO of Innocoll.

Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )